Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Audentes Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: N/A
Year Founded: 2012
Status: Acquired
BioCentury | May 1, 2023
Deals
Iveric takeout spotlights how Astellas builds in new areas of focus
The $5.9B ophthalmology deal also turns M&A attention to rival Apellis
BioCentury | Feb 7, 2023
Management Tracks
Astellas shuffles top management amid push to reshape strategically
As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities
BioCentury | Jan 21, 2023
Finance
Jan. 20 Quick Takes: Moderna vets pick ADARx for new VC’s debut investment
Plus: Clinical hold lifted on Astellas gene therapy, FDA reviewers scrutinize rezafungin’s benefit and updates from Deciphera, Disc and more
BioCentury | Jun 28, 2022
Regulation
June 27 Quick Takes: Kezar’s lupus nephritis data drive after-hours gain
Plus Sutro gains $90M up front in Astellas ADC deal and updates for Nuvation, Astellas, Stealth, Reistone and Axsome
BioCentury | Feb 16, 2022
Emerging Company Profile
Atlas-backed Third Harmonic draws $155M, advances c-Kit inhibitor
Third Harmonic believes selective targeting of master regulator can be effective in multiple allergic and inflammatory indications
BioCentury | Oct 14, 2021
Product Development
A year of gene therapy setbacks
And how they’re shifting the development landscape
BioCentury | Sep 15, 2021
Product Development
What the latest patient death means for gene therapy development
Dosing, pre-existing liver pathology and vector-specific effects all possible contributors to fourth death in Astellas trial
BioCentury | Jul 12, 2021
Management Tracks
Morrison joins Atlas as venture partner; plus Veracyte, FibroGen, T-Knife, Sherlock and more
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | Jun 11, 2021
Management Tracks
Levy leaves Amgen to launch pandemic preparedness alliance; plus Almirall, Vor, Invitae and SAB
Elliott Levy has stepped down as SVP of R&D strategy and operations at Amgen Inc. (NASDAQ:AMGN) to launch International Readiness to Prevent Infectious Viral Disease (INTREPID) Alliance,
Items per page:
1 - 10 of 88